Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expa ...

Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WEST ...

Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WEST ...

Core Viewpoint - Arcutis Biotherapeutics has terminated its promotion agreement with Kowa Pharmaceuticals for ZORYVE, and will take over the sales and promotion responsibilities in the pediatric and primary care markets [1][2][3] Group 1: Agreement Termination - The promotion agreement with Kowa Pharmaceuticals was mutually terminated on January 23, 2026, which involved the sales and promotion of ZORYVE to primary care physicians and pediatricians in the U.S. [1] - Under the termination agreement, Kowa will cease all sales and promotions of ZORYVE, and Arcutis will not be required to make any further payments [3] Group 2: Future Plans - Arcutis plans to assume responsibility for the sales and promotion of ZORYVE in pediatric and primary care settings, with further updates expected during the Q4 earnings call on February 25, 2026 [2] - The company is also expanding its dermatology salesforce to enhance ZORYVE prescriptions in dermatology practices [2] Group 3: Product Information - ZORYVE cream is indicated for the treatment of mild to moderate atopic dermatitis in pediatric patients aged 2 to 5 years and in patients aged 6 years and older [4] - ZORYVE foam is indicated for the treatment of plaque psoriasis and seborrheic dermatitis in patients aged 12 years and older and 9 years and older, respectively [5] Group 4: Safety Information - ZORYVE is contraindicated in patients with moderate to severe liver impairment and has flammability warnings due to its propellant [6] - Common adverse reactions for ZORYVE cream and foam include upper respiratory tract infection, diarrhea, headache, and nausea, with varying percentages across different age groups and formulations [7][8][9][10] Group 5: Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a growing portfolio of advanced targeted topicals [11]

Core Insights - Arcutis Biotherapeutics, Inc. is focused on sustainable growth through its innovative dermatology products, particularly the ZORYVE franchise, which has shown significant commercial momentum [2][5][6] Financial Performance - For Q3 2025, Arcutis reported net product revenue of $99.2 million, marking a 122% increase year-over-year and a 22% increase sequentially from Q2 2025 [5][7][9] - The revenue breakdown includes $30.5 million from ZORYVE cream 0.3%, $18.9 million from ZORYVE cream 0.15%, and $49.8 million from ZORYVE topical foam 0.3% [9] - The company anticipates full-year net product sales for 2026 to be between $455 million and $470 million [14] Product Development and Pipeline - ZORYVE is a potent PDE4 inhibitor approved for treating plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, with ongoing Phase 2 studies for vitiligo and hidradenitis suppurativa [3][4][6] - The company is also advancing its clinical pipeline with ARQ-234, a potential biologic treatment for atopic dermatitis [8] Cost and Expenses - Cost of sales for Q3 2025 was $8.7 million, up from $5.5 million in Q3 2024, reflecting increased sales of ZORYVE [10] - Research and development expenses remained stable at $19.6 million, while selling, general, and administrative expenses rose to $62.4 million due to increased commercialization efforts [11][12] Profitability - Arcutis achieved a net income of $7.4 million, or $0.06 per share, compared to a net loss of $41.5 million in Q3 2024 [13][24]

Core Insights - Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3% for treating plaque psoriasis in patients aged 12 and older, marking a significant advancement in immuno-dermatology [1][5] - ZORYVE foam is a once-daily, steroid-free treatment that is now widely available, addressing the needs of nearly 9 million people in the U.S. living with plaque psoriasis, particularly those with scalp involvement [2][5] Product Details - ZORYVE foam demonstrated significant improvements in clinical trials, achieving Scalp-Investigator Global Assessment (S-IGA) Success in 66.4% of patients compared to 27.8% for the vehicle foam at Week 8 [8] - The foam also provided rapid itch relief, with 65.3% of patients experiencing a clinically significant reduction in scalp itch compared to 30.3% for the vehicle [10] - ZORYVE is indicated for both plaque psoriasis and seborrheic dermatitis, with a focus on hard-to-treat areas such as the scalp and body [14][15] Clinical Trial Results - The approval was supported by positive results from Phase 2 and pivotal Phase 3 trials, enrolling 736 adults and adolescents with mild to severe plaque psoriasis [7] - In the ARRECTOR study, 45.5% of individuals treated with ZORYVE foam achieved Body-IGA Success compared to 20.1% for the vehicle foam at Week 8 [8] - The treatment was well tolerated, with low incidence of adverse events, primarily mild to moderate in severity [12] Market Context - The approval of ZORYVE foam is the fifth for the product in less than three years, highlighting Arcutis' commitment to addressing urgent needs in dermatology [3][5] - The company aims to provide predictable access to ZORYVE through programs that assist patients with adherence and reduce out-of-pocket costs [4][21] Future Engagement - Arcutis will host a virtual Key Opinion Leader Event on June 2, 2025, to discuss the treatment landscape for plaque psoriasis, featuring insights from a leading expert [4][5]

Core Insights - Arcutis Biotherapeutics announced positive results from a pivotal Phase 3 study of ZORYVE (roflumilast) foam 0.3% for treating psoriasis of the scalp and body, published in JAMA Dermatology [1][9] Efficacy Results - ZORYVE foam demonstrated significant improvements in co-primary efficacy endpoints, with 66.4% achieving Scalp-Investigator Global Assessment (S-IGA) Success and 45.5% achieving Body-Investigator Global Assessment (B-IGA) Success at Week 8, compared to 27.8% and 20.1% for the vehicle, respectively (P<0.0001) [4][5] - Clinically meaningful improvements in scalp itch were observed, with 65.3% of ZORYVE-treated individuals achieving a significant reduction in itch compared to 30.3% for the vehicle at Week 8 (P<0.0001) [6][8] - At Week 8, 70.9% of ZORYVE-treated individuals achieved at least 75% improvement in Psoriasis Scalp Severity Index (PSSI-75) compared to 31.3% for the vehicle (P<0.001) [13] Study Design - The ARRECTOR study was a Phase 3, randomized, double-blinded, vehicle-controlled trial involving 432 participants aged 12 years and older across 49 sites in the U.S. and Canada [3][5] Safety and Tolerability - ZORYVE foam was well-tolerated, with low incidence of Treatment Emergent Adverse Events (TEAEs) similar to the vehicle group; common adverse events included headache, diarrhea, and nausea [8][9] - Investigator-rated application-site tolerability showed no evidence of irritation for at least 99.2% of patients at all time points [8] Regulatory Status - A Supplemental New Drug Application (sNDA) for ZORYVE foam 0.3% is under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) action date set for May 22, 2025 [5][11] Market Context - Psoriasis affects approximately nine million people in the U.S., with more than half experiencing scalp involvement, highlighting the need for effective treatment options [10][11]

Core Insights - Arcutis Biotherapeutics reported strong financial performance in Q1 2025, driven by significant demand growth for its ZORYVE portfolio, which offers a safe alternative to steroids [2][6][10] - The company is expanding its market presence with additional indications and coverage for ZORYVE, alongside a promising pipeline of products [2][6][8] Financial Performance - Q1 2025 net product revenue for ZORYVE reached $63.8 million, marking a 196% increase compared to Q1 2024, but a 2% decrease from Q4 2024 [6][10] - Total revenues for Q1 2025 were $65.8 million, compared to $49.6 million in Q1 2024 [10][24] - The net loss for Q1 2025 was $25.1 million, or $0.20 per share, an improvement from a net loss of $35.4 million, or $0.32 per share, in Q1 2024 [14][24] Product Updates - ZORYVE cream and foam are approved for treating various skin conditions, with ZORYVE cream 0.3% being the most prescribed non-steroidal topical treatment for plaque psoriasis and atopic dermatitis [3][4][7] - The company has submitted supplemental New Drug Applications (sNDAs) for ZORYVE cream 0.05% for children and ZORYVE foam for scalp and body psoriasis, with action dates set for October 13, 2025, and May 22, 2025, respectively [7][10] Market Expansion - Over 425,000 prescriptions for ZORYVE cream 0.3% have been filled since its launch, indicating strong physician and patient satisfaction [7] - The company is expanding Medicaid coverage, with over 50% of recipients now covered, and all three largest national Pharmacy Benefit Managers (PBMs) covering the entire ZORYVE portfolio [2][6] Research and Development - Arcutis is advancing its pipeline, including ARQ-255 for alopecia areata, with data expected in mid-2025 [8] - The company is also developing ARQ-234, a potential biologic treatment for atopic dermatitis, with plans to submit an Investigational New Drug application in 2025 [8] Corporate Developments - Latha Vairavan was appointed as Chief Financial Officer effective May 6, 2025 [15] - The company obtained two new U.S. patents related to topical roflumilast compositions in Q1 2025 [15]

Core Insights - Arcutis Biotherapeutics announces the retirement of CFO David Topper and the appointment of Latha Vairavan as the new CFO, effective May 15, 2025, as part of a planned succession [1][3][5] Company Leadership Transition - David Topper has served as CFO since April 2024, playing a crucial role in strengthening Arcutis' financial position, including renegotiating debt and enhancing investor relations [2][3] - Latha Vairavan, with over 20 years of finance experience in the biotech industry, will succeed Topper, bringing a deep understanding of the business and strong industry relationships [4][5] Financial Position and Growth Strategy - Under Topper's leadership, Arcutis has positioned itself for future growth, with a focus on the commercialization of its product ZORYVE [2][3][5] - Vairavan expressed excitement about her new role, emphasizing the company's momentum and commitment to further commercializing ZORYVE for various inflammatory skin conditions [5] Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a growing portfolio that includes three FDA-approved products [5]

Core Insights - Arcutis Biotherapeutics, Inc. will present two posters at the 2025 American Academy of Dermatology annual meeting, focusing on the safety and efficacy of roflumilast cream and foam in treating atopic dermatitis and psoriasis [1][2][3] Group 1: Clinical Trials and Data - The company will present data from two Phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2) that demonstrate the pooled safety and local tolerability of roflumilast cream 0.15% in adults and children with atopic dermatitis who had prior inadequate responses to topical treatments [2][5] - A second presentation will highlight significant improvements in patient-related outcomes with roflumilast foam 0.3% in individuals older than 12 years with psoriasis of the scalp and body [2][7] Group 2: Product Information - Roflumilast cream 0.3% is FDA-approved for the topical treatment of plaque psoriasis in patients aged 6 years and older, while roflumilast cream 0.15% is approved for mild to moderate atopic dermatitis in the same age group [6][9] - ZORYVE foam 0.3% is under FDA review for the treatment of scalp and body psoriasis, with a target action date of May 22, 2025 [8] Group 3: Educational Initiatives - Arcutis will support educational sessions on Culturally Conscious Dermatology™ at the conference, providing attendees with insights into culturally sensitive dermatological care [4]